FMX103 1.5%
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papulopustular Rosacea
Conditions
Papulopustular Rosacea
Trial Timeline
Sep 5, 2017 → Jan 15, 2019
NCT ID
NCT03276936About FMX103 1.5%
FMX103 1.5% is a phase 3 stage product being developed by Vyne Therapeutics for Papulopustular Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT03276936. Target conditions include Papulopustular Rosacea.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03276936 | Phase 3 | Completed |
Competing Products
18 competing products in Papulopustular Rosacea